Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Spending: Lower for Medical Care, Higher Overall

A U.S. survey linked sustained GLP-1 use to $2,586 lower non-drug spending and $6,483 higher total spending per person-year.

Editorial profile: Neil SandersBuy This GLP Editorial Team3 min read
Same-year spending, per person-yearnon-drug medical−$2,586acute care−$2,019total spending+$6,483Adjusted differences from the survey model.

A separate claims study of semaglutide examined medical spending among people who stayed on treatment. In this survey, total spending included prescriptions [1]. Overall spending was higher despite lower adjusted non-drug spending.

Who was included

The study used the U.S. Medical Expenditure Panel Survey. Its main analysis used 2019 and 2021, the two years with usable body mass index data. It included adults with obesity and at least one cardiometabolic risk factor [1].

The primary analysis covered a sample of 7,144 person-year records. Of those, 275 involved sustained GLP-1 use. A person-year is a record of one person for one year. Using only that year limits what the analysis can say about future spending.

How spending differed

Our comparison of national GLP-1 spending studies distinguishes drug spending from total medical spending. This study asks how overall spending differed between the groups it followed.

After adjustment, total spending was $6,483 higher per person-year. Non-drug spending was $2,586 lower. Acute care, which is part of non-drug spending, was $2,019 lower [1].

Before adjustment, non-drug spending was higher in the GLP-1 group. The reversal shows how much the comparison depended on accounting for differences between groups. Unmeasured differences could still affect the estimates [1].

What it says about a household budget

For a personal budget, a six-month cost estimate uses the prices and fees someone actually pays.

The survey found no statistically clear difference in out-of-pocket spending [1]. Its total spending estimate cannot tell a cash buyer what they will pay.

Frequently asked

Did GLP-1 users have lower total spending?
The adjusted estimate was $6,483 higher per person-year. The survey cannot establish whether the drug caused the difference.
How did spending outside the pharmacy differ?
Adjusted non-drug spending was $2,586 lower per person-year. Acute care, one component of that spending, was $2,019 lower.
What does the study say about long-term savings?
It measured spending within a calendar year. It cannot estimate savings or costs that accumulate over several years.

Sources

  1. [1] Çelebi O, et al. (2026). GLP-1 Use, Downstream Medical Spending, and Acute-Care Burden Among Adults with BMI-Defined Obesity: An Overlap-Weighted MEPS Analysis Healthcare. PMID 42588330

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence